Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Intracerebroventricular injection of ouabain causes mania-like behavior in mice through D2 receptor activation. / Lopachev, Alexander; Volnova, Anna; Evdokimenko, Anna; Abaimov, Denis; Timoshina, Yulia; Kazanskaya, Rogneda; Lopacheva, Olga; Deal, Alex; Budygin, Evgeny; Fedorova, Tatiana; Gainetdinov, Raul.
в: Scientific Reports, Том 9, № 1, 15627, 30.10.2019.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Intracerebroventricular injection of ouabain causes mania-like behavior in mice through D2 receptor activation
AU - Lopachev, Alexander
AU - Volnova, Anna
AU - Evdokimenko, Anna
AU - Abaimov, Denis
AU - Timoshina, Yulia
AU - Kazanskaya, Rogneda
AU - Lopacheva, Olga
AU - Deal, Alex
AU - Budygin, Evgeny
AU - Fedorova, Tatiana
AU - Gainetdinov, Raul
PY - 2019/10/30
Y1 - 2019/10/30
N2 - Intracerebroventricular (ICV) administration of ouabain, an inhibitor of the Na, K-ATPase, is an approach used to study the physiological functions of the Na, K-ATPase and cardiotonic steroids in the central nervous system, known to cause mania-like hyperactivity in rats. We describe a mouse model of ouabain-induced mania-like behavior. ICV administration of 0.5 µl of 50 µM (25 pmol, 14.6 ng) ouabain into each lateral brain ventricle results in increased locomotor activity, stereotypical behavior, and decreased anxiety level an hour at minimum. Fast-scan cyclic voltammetry showed that administration of 50 µM ouabain causes a drastic drop in dopamine uptake rate, confirmed by elevated concentrations of dopamine metabolites detected in the striatum 1 h after administration. Ouabain administration also caused activation of Akt, deactivation of GSK3β and activation of ERK1/2 in the striatum of ouabain-treated mice. All of the abovementioned effects are attenuated by haloperidol (70 µg/kg intraperitoneally). Observed effects were not associated with neurotoxicity, since no dystrophic neuron changes in brain structures were demonstrated by histological analysis. This newly developed mouse model of ouabain-induced mania-like behavior could provide a perspective tool for studying the interactions between the Na,K-ATPase and the dopaminergic system.
AB - Intracerebroventricular (ICV) administration of ouabain, an inhibitor of the Na, K-ATPase, is an approach used to study the physiological functions of the Na, K-ATPase and cardiotonic steroids in the central nervous system, known to cause mania-like hyperactivity in rats. We describe a mouse model of ouabain-induced mania-like behavior. ICV administration of 0.5 µl of 50 µM (25 pmol, 14.6 ng) ouabain into each lateral brain ventricle results in increased locomotor activity, stereotypical behavior, and decreased anxiety level an hour at minimum. Fast-scan cyclic voltammetry showed that administration of 50 µM ouabain causes a drastic drop in dopamine uptake rate, confirmed by elevated concentrations of dopamine metabolites detected in the striatum 1 h after administration. Ouabain administration also caused activation of Akt, deactivation of GSK3β and activation of ERK1/2 in the striatum of ouabain-treated mice. All of the abovementioned effects are attenuated by haloperidol (70 µg/kg intraperitoneally). Observed effects were not associated with neurotoxicity, since no dystrophic neuron changes in brain structures were demonstrated by histological analysis. This newly developed mouse model of ouabain-induced mania-like behavior could provide a perspective tool for studying the interactions between the Na,K-ATPase and the dopaminergic system.
KW - ENDOGENOUS CARDIOTONIC STEROIDS
KW - SIGNAL-REGULATED KINASE
KW - DOPAMINE RELEASE
KW - ANIMAL-MODELS
KW - RAT-BRAIN
KW - HYPERACTIVITY
KW - DISORDER
KW - NEURONS
KW - LITHIUM
KW - AKT
UR - http://www.scopus.com/inward/record.url?scp=85074295582&partnerID=8YFLogxK
UR - http://www.mendeley.com/research/intracerebroventricular-injection-ouabain-causes-manialike-behavior-mice-through-d2-receptor-activat
U2 - 10.1038/s41598-019-52058-z
DO - 10.1038/s41598-019-52058-z
M3 - Article
C2 - 31666560
AN - SCOPUS:85074295582
VL - 9
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 15627
ER -
ID: 48571106